{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:39:39Z","timestamp":1781123979300,"version":"3.54.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after cessation of the drug without relapse (2 years of follow-up). To the best of our knowledge, this is the first case describing FSGS lesions associated with the use of an interleukin-23 inhibitor.<\/jats:p>","DOI":"10.1093\/ckj\/sfad161","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T18:21:51Z","timestamp":1688581311000},"page":"1701-1702","source":"Crossref","is-referenced-by-count":8,"title":["Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab"],"prefix":"10.1093","volume":"16","author":[{"given":"Marijke","family":"Stryckers","sequence":"first","affiliation":[{"name":"Department of Nephrology , H. Hart-Ziekenhuis, Lier , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"Van Oevelen","sequence":"additional","affiliation":[{"name":"Department of Nephrology , H. Hart-Ziekenhuis, Lier , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Koshy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Ziekenhuis Oost-Limburg, Genk , Belgium"},{"name":"Department of Immunology and Infection, Biomedical Research Institute of the Hasselt University , Diepenbeek , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaryllis H","family":"Van Craenenbroeck","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Laboratory of Nephrology of the KU Leuven , Leuven Belgium"},{"name":"Department of Neprology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"2023092902520011900_bib1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2023092902520011900_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2023092902520011900_bib3","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'Agati","year":"2011","journal-title":"N Engl J Med"},{"key":"2023092902520011900_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520011900_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.autrev.2018.08.006","article-title":"Th17 cells in renal inflammation and autoimmunity","volume":"18","author":"Dolff","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad161\/50910430\/sfad161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1701\/51788603\/sfad161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1701\/51788603\/sfad161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:53:05Z","timestamp":1695955985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/10\/1701\/7220549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":5,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,6]]},"published-print":{"date-parts":[[2023,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad161","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,6]]}}}